natgillin/translations-raw huggingface dataset:
The method of claim 1, wherein said source of human HSCs is bone marrow, thymus, peripheral blood, fetal liver, or embryonic yolk sac. 
Postupak prema zahtjevu 9, naznačen time da je navedeni izvor humanih krvotvornih matičnih stanica (HKMS) koštana srž, timus, ili periferna krv.
monitoring the catalyst temperature using a temperature sensor in or near the catalyst so that an increase in temperature triggers an increase in the air input to the catalyst to reduce the temperature. 
- < praćenje temperature katalizatora korištenjem osjetnika temperature u katalizatoru ili blizu katalizatora tako da povećanje temperature izaziva povećanje dovoda zraka u katalizator da bi se ta temperatura smanjila.
The composition according to claim 1, wherein the viral cultures are selected from the group consisting of Flavivirus, Togavirus, Coronavirus, Rhabdovirus, Filovirus, Paramyxovirus, Orthomyxovirus, Bunyavirus, Arenavirus, Retrovirus, Hepadnavirus, Pestivirus, Picornavirus, Calicivirus, Reovirus, Parvovirus, Papovavirus, Adenovirus, Herpes virus, and Poxvirus. 
Spoj sukladno patentnom zahtjevu 1, gdje su kulture virusa odabrane iz grupe koju čine flavi virus, toga virus, korona virus, rabdo virus, filo virus, paramiksovirus, ortomiksovirus, bunyavirus, arenavirus, retrovirus, hepadnavirus, pestivirus, pikorna virus, calicivirus, reovirus, parvovirus, papovavirus, adenovirus, herpes virus i virus boginja.
2 respectively, wherein each of said regions comprises at least 4 or 5 amino acids and wherein said assay is not a manual coated-tube-Akridiniumester sandwich assay. 
2), gdje svakoje od navedenih područja sadrži najmanje 4 ili 5 aminokiselina, gdje je navedeni test manualni sendvič test s epruvetama obloženim akridinijevim esterom, gdje je
is a substituent on a nitrogen atom contained in ring A selected from the group consisting of hydrogen, C1-4alkyl, and aryl; 
R> je supstituent na atomu dušika prstena A izabran iz skupine koju čine vodik i C,yalkil;
The pharmaceutical composition according to claim 7, wherein the antigen presenting cell is a dendritic cell. 
Farmaceutski sastav prema zahtjevu 7, gdje je stanica koja predstavlja antigen dendritična stanica.
The ploughshare (2) in accordance with claim 4, wherein the abutment surface (42) is single-curved around an axis which is parallel to the longitudinal axis (SA) of the plough point (3). 
Lemeš (2) u skladu sa zahtjevom 4, naznačen time da je potporna površina (42) jednostruko zakrivljena oko osi koja je paralelna s uzdužnom osi (SA) vrha pluga (3).
The isolated population of placental stem cells of claim 20, wherein said autoimmune disease is multiple sclerosis. 
Izdvojena populacija matičnih stanica iz posteljice u skladu s patentnim zahtjevom 20, naznačena time što je navedena autoimunosna bolest multipla skleroza.
N-terminal hydrophilic fragment Soybean 7S Globulin a' Subunit consisting of 142 amino acid residues from said N-terminal side. 
N-terminalni hidrofilni fragment a' podjedinice 7S globulina sjemenke soje, naznačen time da se sastoji od 142 aminokiselinska ostatka od rečenog N-terminalnog kraja.
The method according to claim 2, wherein 1 to 10 consecutive nucleotides from a 5′ terminus of an antisense strand of the siRNA are converted into DNA. 
siRNA u skladu sa zahtjevom 1 ili 2, naznačena time, da se 1 do 10 uzastopnih nukleotida iz 5' terminusa antisens lanca siRNA pretvaraju u DNA.
The treatment step includes at least one size reduction step for reducing the size of the extracted material and/or at least one washing and separation step for washing and separating the liquid phase from the solid cell phase, said treatment step being carried out using the device and method of the present invention. 
Uređaj kao što je navedeno u jednom ili više prethodnih patentnih zahtjeva, naznačen time da su osigurana sredstva za kompresiju ili aspiraciju tekuće komponente i/ili čvrste komponente masti u ili iz komore za pranje (101) kontejnera za pranje i odvajanje (1) i/ili komore (201) za smanjivanje kontejnera (2) za smanjivanje veličine.
The method of claim 23, wherein the carbon nanotubes are multi-wall carbon nanotubes. The method of claim 23, wherein the carbon nanotubes are single-wall carbon nanotubes. The method of claim 23, wherein the conductive composite layer is deposited on the metallic antenna underbody through a technique selected from the group consisting of dip coating, spin coating, printing, spray depositing, and combinations thereof. 
Postupak prema bilo kojem od zahtjeva 9 - 12, pri čemu su ugljične nanocijevi višeslojne ugljične nanocijevi; ili pri čemu su ugljične nanocijevi jednoslojne ugljične nanocijevi. Postupak prema bilo kojem od zahtjeva 9 - 13, pri čemu korak deponiranja sadrži tehniku koja je izabrana iz grupe koja se sastoji od deponiranja slojeva umakanjem, deponiranja slojeva na rotirajuću podlogu djelovanjem centrifugalne sile, metoda štampe, deponiranja slojeva raspršivanjem, i njihovih kombinacija.
The process of claim 30 wherein the palladium catalyst is Pd(P(tBu3)2 and the base is 1.2 equivalents of DIPEA. 
Postupak prema zahtjevu 30 gdje je paladijev katalizator PA(P(£Bu;), i baza je 1.2 ekvivalenata DIPEA.
Preferably the invention relates to an extended release tablet formulation, wherein the anionic polymer is selected from the group of optionally crosslinked acrylic acid polymers, methacrylic acid polymers, alginates and carboxymethylcellulose. 
Formulacija tablete produljenog oslobađanja u skladu sa zahtjevom 1, naznačena time, da je anionski polimer izabran iz skupine koju čine po želji umreženi polimeri akrilne kiseline, polimeri metakrilne kiseline, alginati i karboksimetilceluloza.
A pharmaceutical composition comprising the antibody or antibody fragment thereof according to any one of claims 1 to 5 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak naznačen time da sadrži bispecifično antitijelo ili njegov bispecifični fragment antitijela prema bilo kojem zahtjevu 1 ili 21 farmaceutski prihvatljiv nosač.
Hetcy, Aryl or HAR, each being optionally substituted with 1-3 members selected from the group consisting of: halo, C1-4alkyl, C1-4alkoxy, haloC1-4alkyl and haloC1-4alkoxy groups; and R"' representing H or R"; 
(b) Hetcy, Aril ili HAR, od kojih je svaki po izboru supstituiran s 1-3 člana izabrana iz grupe koja obuhvaća skupine: halogen, C,ualkil, Cy.galkoksi, halogenC,.alkil i halogenC; valkoksi; iR'"' predstavlja H ili R";
The composition for use according to any one of claims 1 to 4, wherein the dose of desmopressin free base is supplied in the form of the acetate salt of desmopressin. 
Pripravak za uporabu prema zahtjevu 1-3, naznačen time da je doza slobodne baze dezmopresina u obliku acetatne soli dezmopresina.
The compound for use according to any preceding claim, further comprising administration of an additional anti-viral agent, optionally wherein the additional anti-viral agent is laninamivir, oseltamivir, zanamivir, or peramivir. 
Spoj za primjenu prema zahtjevu 9, naznačen time da je dodatni antivirusni agens izabran iz grupe koja se sastoji od laninamivira, oseltamivira, zanamivira, i peramivira.
mixing the neutral phospholipid, the cholesterol and a buffer to obtain a mixture; preparing the blank liposome from the mixture using at least one of a high-pressure homogenizer and an extrusion equipment; and 
miješanje neutralnog fosfolipida, kolesterola i pufera ovisno o željenoj formulaciji, zatim priprema praznog liposoma sa željenom veličinom čestica uporabom opreme homogenizatora s visokim pritiskom i/ili za ekstruziju;
WO9909063 discloses the production of IL-18BP in mammalian cells in the application. 
U WO9909063 objavljena je proizvodnja IL-18BP u stanicama sisavaca.
An aqueous pharmaceutical formulation with pH between 3.4 and 4.6 comprising insulin glargine for use in the treatment of Type I and Type II Diabetes Mellitus in a patient, wherein the concentration of insulin glargine is 200-500 U/mL being equimolar to 200-500 IU human insulin. 
Vodeni farmaceutski pripravak sa pH između 3.4 1 4.6 koji sadrži inzulin glargin naznačen time da je za uporabu u postupku za liječenje dijabetes melitusa tipa I i tipa IL, pri čemu pripravak sadrži 270 - 330 U/mL inzulin glargina.
A pharmaceutical composition comprising a compound of Formula (I) according to claims 1-8 and a pharmaceutically acceptable diluent and/or carrier. 
Farmaceutski pripravak koji sadrži spoj formule (1) prema patentnim zahtjevima 1-7 i farmaceutski prihvatljiv razrjeđivač i/ili nosač.
A shoe according to claim 7, wherein said different material of said insert (30, 66) has a different friction coefficient with respect to the material that composes the base cushioning element. 
Obuća sukladno zahtjevu 4, pri čemu različiti materijal umetka (30, 66) ima različiti koeficijent trenja u odnosu na materijal koji čini osnovni element za ublažavanje.
The peptide for use according to Claim 3, wherein said fusion protein comprises the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). 
Peptid u skladu s patentnim zahtjevom 3, pri čemu navedeni fuzionirani protein sadrži N-terminalne aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (Ii).
The method according to claim 4, characterized in that the microbial growth medium comprises at least 50 millimol potassium per liter of medium. 
Metoda prema zahtjevu 4, naznačena time da podloga za uzgoj mikroba sadrži najmanje 50 milimola kalija na litru podloge.
[Paragraph 4] The modified IgG4 Fc fragment of paragraph 1, wherein the hinge region was mutated by the deletion of 1 to 8 continuous or discontinuous amino acid(s) comprising a Cys residue at the 11th position. 
Modificirani IgG4 Fc fragment prema zahtjevu 1, naznačeno time da je zglobna regija mutirana putem brisanja od 1 do 8 uzastopne/ih ili neuzastopne/ih aminokiselina sadržeći Cis ostatak na osmom položaju.
After power up and enablement of the “Tons treated” function, pushing “tons treated” button 116 will cause controller 80 to read the theoretical revolutions of the gear motor for the set “rate value” off of the look-up table. 
Poslije uključivanja napajanja i aktiviranja funkcije "obrađeno tona", pritiskivanjem na gumb 116, "obrađeno tona", kontrolor 80 očitat će teoretske obrte motora za podešenu "veličinu brzine" iz tablice za potraživanje.
A pharmaceutical composition comprising a compound of any one of claims 1 to 7, and a pharmaceutically acceptable carrier, additive or diluent. 
[image] Farmaceutska kompozicija naznačena time što sadrži spoj prema patentnom zahtjevu 1 i farmaceutski prihvatljiv nosač ili razblaživač.
This further polymorphic form of 3-phenylsulfonyl-8-piperazin-1-yl-quinoline is referred to as Form III. 
Ovaj daljnji polimorfni oblik 3-femlsulfonil-8-piperazin-1-ilkinolina navodi se kao Oblik III.
purifying the polypeptide, wherein the polypeptide contains no extraneous sequences. 
(h) pročišćavanje polipeptida, pri čemu polipeptid ne sadrži tuđinske sekvence.
The apparatus according to claim 1, wherein the first tank comprises an air inlet. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što prvi spremnik sadrži miješanu tekućinu ili ulaz zraka.
refilling all said micro trenches to a suitable level with a suitable filling material after said plurality of ducts/cables have been routed to their said endpoints; 
- punjenja svih navedenih mikro-rovova na odgovarajuću razinu s odgovarajućim materijalom za punjenje nakon što su navedeni pluralitet kanala / kabela usmjereni do njihovih navedenih krajnjih točaka;
The retinal derivative for use according to claim 2, which is a 9-cis-retinyl ester of a C3 to C22 polycarboxylate. 
Derivat retinala za upotrebu u skladu s patentnim zahtjevom 2, naznačen time, da je to 9-cis-retinil ester C3-C22 polikarboksilata.
In some situations, it can be desirable to have an open time being as long as possible, for example, if a large stack of pieces of wood is formed that subsequently should be pressed. 
U nekim slučajevima može biti poželjno da se ima otvoreno vrijeme stoje dulje moguće, na primjer, ako je pripremljena velika količina komada koji se odmah nakon toga trebaju prešati.
Characterized in that it is included a sliding corridor (10) within is arranged slidably said tensioning device (7), said sliding corridor being closed at the front and rear. 
pušku karakterizira klizni put (10) unutar kojega je smješten mehanizam za napinjanje (7) koji se po njemu pomiče klizanjem, dok je sam put zatvoren s prednje 1 zadnje strane.
The mixture is heated to approximately 55° C. A one molar equivalence of benzensulfonic acid delivered as a stock solution is added. 
Smjesu se grije do približno 55 *C. Doda se 1 M ekvivalent benzensulfonske kiseline, dobiven kao matična otopina.
a sequence of amino acids that is at least 80% identical to a heavy chain variable domain sequence of H1-H27; 
slijed aminokiselina najmanje 80% identičan slijedu SEQ ID NO:361; di.
is alkyl; wherein alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and alkoxy are optionally substituted with at least one group selected from halo, hydroxyl, amino, cyano, nitro, mercapto, alkoxycarbonyl, amido, carboxy, alkanesulfonyl, alkylcarbonyl, carbamido, carbamyl, carboxyl, thioureido, thiocyanato, sulfonamido, alkyl, alkenyl, alkynyl, alkyloxy, aryl, heteroaryl, cycloalkyl and heterocycloalkyl, in which alkyl, alkenyl, alkynyl, alkyloxy, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl may further substituted; 
R, je alkil; pri čemu su alkil, cikloalkil, heterocikloalkil, aril, heteroaril, 1 alkoksi opcionalno supstituirani sa barem jednom skupinom odabranom od halo, hidroksil, amino, cijano, nitro, merkapto, alkoksikarbonil, amido, karboksi, alkansulfonil, alkilkarbonil, karbamido, karbamil, karboksil, tioureid, tiocijanat, sulfonamido, alkil, alkenil, alkinil, alkiloksi, aril, heteroaril, cikloalkil i heterocikloalkil, pri čemu alkil, alkenil, alkinil, alkoksi, aril, heteroaril, cikloalkil, i heterocikloalkil mogu biti daljnje supstituirani; ili njegova farmaceutski prihvatljiva sol.
A dispenser for dispensing a dose of a gaseous, gas borne or droplet substance from a substance source (C), the dispenser comprising: 
Dispenzer za dispenziranje doza plinovite, prenosive plinom ili u obliku kapljica supstance iz izvora (C) supstance, pri čemu dispenzer sadrži: tijelo (1) za prijem izvora supstance, pri čemu tijelo ima pisak (2);
The fusion protein for use according to claim 2 wherein there are no residues heterologous to the enzyme present C-terminal to the MTS and cleavage of the said MTS generates an enzyme with the native sequence, which is readily integrated into a conformationally-sensitive multi-component enzyme complex. 
Fuzijski protein za uporabu u skladu s patentnim zahtjevom 2 pri čemu nema ostataka heterolognih enzimu prisutnom C-terminalno prema MTS 1 cijepanje navedenog MT$S stvara enzim s nativnim slijedom, koji se odmah integrira u konformacijski osjetljiv višekomponentni enzimski kompleks.
administering the dosage form to the mammal. 
(c) davanje doze sisavcu.
The pharmaceutically acceptable salt of claim 1, which is a salt of an inorganic or organic acid selected from the group consisting of hydrochloric, hydrobromic, hydroiodic, sulfuric, phosphoric, acetic, trifluoroacetic, propionic, oxalic, malic, maleic, succinic, malonic, aspartic, or glutamic acid. 
Soli spojeva opće formule (I), naznačeni time da su soli anorganksih ili organskih kiselina odabranih od sljedećih: klorovodčna, bromovodična, jodovodična, sumporna, fosforna, octena, trifluoroctena, propionska, oksalna, jabučna, maleinska, jantarna, malonska, asparaginska 1 glutaminska kiselina.
to determine whether said level of lactoferrin is below a predetermined cut-off value; and to predict the functional outcome of Alzheimer's disease in the subject evaluating the result of the previous determination. 
- daodređuju da li je navedeni razina laktoferina ispod unaprijed određene granične vrijednosti; i - da predvide funkcionalni ishod Alzheimerove bolesti kod subjekta procjenom rezultata prethodnog određivanja,
Intravenous formulation according to claim 2, wherein the inositol phosphate is inositol hexaphosphate. 
Pripravak za uporabu prema zahtjevu 3, gdje inozitol fosfat jest inozitol heksafosfat.
A signal repeater as claimed in claim 21, wherein the inductors are coaxial with the cable. 
Prijenosnik signala kao što se zahtijeva u zahtjevu 21, naznačen time, da su induktori (69,70) koaksijalni s kabelom (61).
The method of item 48, wherein the first temperature is about 45 to about 55 °C. 
(a) kontakta natrijevog nitrita s vodom pri prvoj temperaturi od 45 do 55 * € u inertnoj atmosferi;
The method of claim 1 wherein the gastrointestinal disease is caused at least in part by an organism selected from the group consisting of Salmonella, Shigella, Staphylococcus, Campylobacter, Helicobacter, Clostridium, Escherichia coli, and Yersinia, and combinations thereof. 
Spoj prema bilo kojem od zahtjeva 1 do 14 za uporabu u akutnom liječenju bolesnika koji je izložen jednom ili više organizama izabranih iz grupe koju čine Bacillus anthracis, Yersinia pestis, Francisella tularensis i Burkholderia mallei, i njihove kombinacije.
Xaa at position 230 is Lys or is absent. 
Xaa na položaju 230 je Lys ili je odsutan.
except for mixtures comprising pyroxsulam or one of its environmentally compatible salts. 
Osim smjesa koje sadrže piroksulam ili neku od njegovih soli prihvatljivih za okoliš.
Preferably, the taper substantially extends over the whole length of the post in order to allow homogenous light irradiation over the total length of the circumferential surface. 
Zubni most u skladu s patentnim zahtjevom 1, naznačen time što se navedeni ušiljeni dio pruža preko najmanje jedne trećine ukupne duljine navedenog mosta.
wherein L, L2, L3, L4, R1, m, n, V, W, X, Y and Z are as defined in formula (I), with a compound of formula (III) or a suitable salt thereof in the presence of a suitable reducing agent (e.g. sodium cyanoborohydride, sodium triacetoxyborohydride, or hydrogen in the presence of a suitable palladium on carbon or platinum oxide catalyst); or 
Z N1 Ray gdje su L, L', L', L', R!, m, n, V, W, X, Y i Z kako je definirano u formuli (I), sa spojem sa formulom (III) ili njegovom soli u prisutnosti redukcijskog sredstva; ili od reakcije spoja sa formulom (V), ili njegove soli,
Thus, the effect of the loading flow rate on the capture of r-hIL-18BP in the MEP HYPERCEL® column was evaluated. 
Prema tome je procijenjen utjecaj brzine nanošenja uzorka na hvatanje r-hIL-8BP u koloni MEP HyperCel.
With reference to Figure 1A, the outer ribs 3 and the inner ribs 4 have a substantially rectangular profile in axial section and the longitudinal dimension a of the outer ribs 3 is substantially equal to the longitudinal dimension a of the inner ribs 4. 
Na slici LA, vanjski nabori 3 kao i unutarnji nabori 4, u osnom presjeku imaju izrazit pravokutni profil, dok je dužinska dimenzija a vanjskih nabora 3 u suštini jednaka dužinskoj dimenziji unutarnjih nabora 4.
For oral administration, the pharmaceutical composition can be in the form of, for example, a tablet, capsule, suspension or liquid. 
Za oralnu primjenu, farmaceutski pripravak može biti u obliku, na primjer, tablete, kapsule, suspenzije ili tekućine.
Tool according to claim 1, characterised in that the face comprises flat surface inside the periphery, in operation the flat surface provides underpressure and suction effect of the tool toward the surface according to the venturi effect. 
Alat prema patentnom zahtjevu 1, naznačen time da ploha za čišćenje ima ravnu površinu unutar oboda, u radu ravna površina osigurava podtlak 1 efekt usisavanja alata prema površini koju treba očistiti po principu Venturijevog efekta.
The compound according to claim 12, wherein the said disorder is anxiety, alzheimer's disease, depression, convulsive disorders, obsessive-compulsive disorders, migraine, headache, cognitive memory disorders, ADHD, personality disorders, psychosis, paraphrenia, psychotic depression, parkinson's disease, mania, schizophrenia, panic disorders and sleep disorders. 
Spoj prema zahtjevu 12, naznačen time da je navedeni poremećaj anksioznost, Alzheimerova bolest, depresija, konvulzivni poremećaji, opsesivno-kompulzivni poremećaji, migrena, glavobolja, kognitivni poremećaji pamćenja, poremećaj pozornosti s hiperaktivnošću (ADHD), poremećaji osobnosti, psihoza, parafrenija, psihotična depresija, Parkinsonova bolest, manija, šizofrenija, panični poremećaji i poremećaji sna.
treating cancer in a subject by inhibiting a cancer stem cell survival and/or self-renewal, comprising administering to a cancer stem cell an effective amount of the compound or enantiomer, diastereomer, tautomer, or pharmaceutically-acceptable salt or solvate thereof; 
liječenju raka u subjekta inhibicijom preživljavanja matičnih stanica raka i/ili samo-obnove, koje obuhvaća primjenu učinkovite količine spoja formule VIII na matične stanice raka;
encode blocks (40) of the array of information samples by using a transform in order to transfer the information samples within each block (40) from spatial domain into spectral domain in order to obtain transform coefficient blocks, and inserting, by entropy encoding, information on the transform coefficient blocks into the data stream by encoding a significance map indicating positions of significant transform coefficients within a transform coefficient block into the data stream, by 
Dekoder na bazi transformacije, naznačen time, da je konfiguriran za dekodiranje bloka koeficijenata transformacije uporabom uređaja (150) za dekodiranje signifikacijske mape iz protoka podataka, koja prikazuje pozicije sigmifikantnih koeficijenata transformacije unutar bloka koeficijenata transformacije, prema bilo kojem od zahtjeva 1 do 9, te za izvođenje (152) transformacije iz spektralne domene u prostornu domenu u bloku koeficijenata transformacije.
The specific activity of IL-18BP is calculated according to the following formula: 
Specifična aktivnost IL-18BP izračunata je sukladno slijedeće formule:
The compound of claim 2, which is a compound of formula IA2, IA3, IA4 or IA5: 
Spoj u skladu s patentnim zahtjevom 2, naznačen time, da je spoj formule IA2, IA3, TA4 ili IAS:
A pharmaceutical formulation according any one of the preceding claims for use in a method of treating a disease or disorder in a subject, the method comprising administering the formulation to a subject in an amount effective to treat the disease or disorder. 
Farmaceutska formulacija prema zahtjevu 1, naznačena time, da je za uporabu u postupku liječenja bolesti ili poremećaja kod subjekta, pri čemu taj postupak obuhvaća davanje subjektu učinkovite količine formulacije u svrhu liječenja bolesti ili poremećaja.
The cell according to claim 12, wherein said bicontinuous micro-emulsion is obtainable by mixing (i) a first bicontinuous micro-emulsion comprising a hydrophilic phase, a hydrophobic phase and a surface-active agent, to which bicontinuous micro-emulsion a salt or a metal complex of a catalyst material is supplied to the hydrophilic phase, and a (ii) second bicontinuous micro-emulsion comprising a hydrophilic phase, a hydrophobic phase and a surface-active agent, further containing a reducing material, wherein upon mixing a precipitation reaction takes place on which the catalyst is formed. 
Bikontinuirana mikroemulzija koja uključuje hidrofilnu fazu, hidrofobnu fazu 1 površinski reaktivnu supstancu; kao i katalizator u barem jednoj od hidrofilne faze i hidrofobne faze, koji je katalizator generiran in situ u reakciji taloženja redukcijom metalnog kompleksa, navedenu bikontinuiranu emulziju moguće je dobiti miješanjem (i) prve bikontinuirane mikroemulzije koja sadrži hidrofilnu fazu, hidrofobnu fazu i površinski aktivni agens, na koji bikontinuiranu emulziju se dovodi kompleks soli ili metala katalitičkog materijala u hidrofilnoj fazi, i (ii) drugu bikontinuiranu mikroemulziju koja sadrži hidrofilnu fazu, hidrofobnu fazu i površinski aktivni agens, nadalje sadrži reducirajući materijal, pri čemu miješanjem dolazi do reakcije taloženja u kojoj se formira katalizator.